| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $35.5M | +43.2% | +185.9% |
| SG&A Expense | $8.1M | +24.6% | +63.1% |
| Operating Income | -$88.6M | -223.6% | -409.5% |
| Income Tax | $0 | — | — |
| Net Income | -$83.2M | -223.6% | -420.7% |
| EPS (Basic) | -$3.10 | -87.9% | -26.5% |
| EPS (Diluted) | -$3.10 | -87.9% | -26.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $293.7M | -42.5% | +130.5% |
| Accounts Receivable | $1.9M | +0.1% | +9.5% |
| Current Assets | $442.8M | -16.7% | +182.5% |
| Total Assets | $518.6M | -2.9% | +219.5% |
| Current Liabilities | $95.8M | +196.5% | +116.2% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$103.5M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | -$176.3M | — | — |
| Financing Cash Flow | $383.6M | — | — |
| Free Cash Flow | -$103.5M | — | — |
| $96.3M |
| +190.4% |
| +106.1% |
| Stockholders' Equity | $422.4M | -15.7% | +265.3% |